Overview

A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the diagnostic efficacy (specificity and sensitivity) of flurpiridaz F18 injection PET myocardial perfusion imaging (MPI) compared to single photon emission computed tomography (SPECT) MPI in the detection of significant coronary artery disease (CAD) as defined by invasive coronary angiography (ICA) or a documented history of Myocardial Infarction (MI).
Phase:
Phase 3
Details
Lead Sponsor:
Lantheus Medical Imaging
Treatments:
Technetium Tc 99m Sestamibi
Technetium tc-99m tetrofosmin